Drug
AP 1903 reagent clinical trials
Also written AP1903 and Rimiducid.
- studies test it
- 11
- open now
- 2
- in phase 3
- 0
- first study started
- 2009
Keep track of what changes. Save the AP 1903 reagent studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 6
Bellicum Pharmaceuticals (4) · M.D. Anderson Cancer Center (2) · Baylor College of Medicine (1) · UNC Lineberger Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Beijing Biotech (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (5) · Fludarabine (3) · Rivogenlecleucel (3) · Bendamustine (1) · Fludarabine phosphate (1)
Studies
Open first, then newest update. How each study uses AP 1903 reagent is read from its arms, and is right about nine times in ten.
Testing it · 11
- Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)RecruitingPhase 1M.D. Anderson Cancer CenterNCT06066424Written as Rimiducid
- Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic CarcinomaRecruitingPhase 1/2Beijing BiotechNCT07598955Written as Rimiducid (AP1903)
- Administration of Donor T Cells With the Caspase-9 Suicide GeneActive, not recruitingPhase 1Baylor College of MedicineNCT01494103Written as AP1903
- Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaActive, not recruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT03696784Written as AP1903
- T-Cell Therapy for Advanced Breast CancerActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT02792114Written as AP1903
- A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT02107963Written as AP1903
- Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant DiseasesTerminatedPhase 1Bellicum PharmaceuticalsNCT02231710Written as BPX-501 and Rimiducid
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruitingPhase 1/2Bellicum PharmaceuticalsNCT03301168Written as Rimiducid
- Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo TransplantActive, not recruitingPhase 1Bellicum PharmaceuticalsNCT03459170Written as rimiducid
- MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate CancerCompletedPhase 1Bellicum PharmaceuticalsNCT00868595Written as AP1903
- Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide GeneTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT01875237Written as AP1903
Given in every arm · 23 — AP 1903 reagent is usual care beside what is tested
- Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The PeritoneumRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07509008Written as Rimiducid (AP1903)
- Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast CancersNot yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07553390Written as Rimiducid
- Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin LymphomaNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07164469Written as Rimiducid (AP1903)
- A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)WithdrawnPhase 1Genentech, Inc.NCT06984341Written as Rimiducid
- Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)Active, not recruitingPhase 1M.D. Anderson Cancer CenterNCT06358430Written as Rimiducid (AP1903)
- Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALLActive, not recruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT03016377Written as Rimiducid
- P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell MalignanciesActive, not recruitingPhase 1Poseida Therapeutics, Inc.NCT06014762Written as Rimiducid
- P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple MyelomaActive, not recruitingPhase 1Poseida Therapeutics, Inc.NCT04960579Written as Rimiducid
- Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid TumorsTerminatedPhase 1Regeneron PharmaceuticalsNCT02744287Written as Rimiducid
- P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1Poseida Therapeutics, Inc.NCT05239143Written as Rimiducid
- P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)TerminatedPhase 1Poseida Therapeutics, Inc.NCT04249947Written as Rimiducid
- P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)TerminatedPhase 1/2Poseida Therapeutics, Inc.NCT03288493Written as Rimiducid
- Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid MalignanciesCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03056339Written as AP1903
- Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal MelanomaTerminatedPhase 1/2Bellicum PharmaceuticalsNCT02743611Written as Rimiducid
- Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedPhase 1/2Bellicum PharmaceuticalsNCT02065869Written as Rimiducid
- Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDSTerminatedPhase 2/3Bellicum PharmaceuticalsNCT03699475Written as rimiducid
- Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyTerminatedPhase 1/2Bellicum PharmaceuticalsNCT03733249Written as Rimiducid
- Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell TransplantActive, not recruitingPhase 1/2Bellicum PharmaceuticalsNCT01744223Written as Rimiducid
- Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic TransplantActive, not recruitingPhase 1Bellicum PharmaceuticalsNCT02477878Written as Rimiducid
- T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple MyelomaCompletedPhase 1National Cancer Institute (NCI)NCT03958656Written as Rimiducid
Showing 20 of 23.
Codes
What other systems call AP 1903 reagent · ClinicalTrials.gg INT004331
- MeSH (NLM) C423866AP 1903 reagentConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) H564L1W5J2RIMIDUCIDConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C423866 | AP 1903 reagent | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | H564L1W5J2 | RIMIDUCID | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.